In This Section
Antoni Ribas, MD, PhD

Antoni Ribas, MD, PhD

University of California Los Angeles Medical Center
Los Angeles, California 

Class of 2020

For his seminal clinical research contributions that have led to the development of pembrolizumab as the first-in-class approved anti-PD-1 immunotherapy for the treatment of melanoma, for his characterization of BRAF, CTLA-4, and MEK in cancer, and for deciphering the molecular mechanisms responsible for immunotherapeutic resistance, which have since fueled additional efforts to understand the relationship between the immune system and cancer.